Facts & Figures - Bayer HealthCare Pharmaceuticals

At a glance
R&D highlights
Research locations

Research and Development at Bayer HealthCare Pharmaceuticals

Improving patients' quality of life with innovation

Bayer HealthCare invests considerable resources in the research and development of new drugs, with the aim of improving patients' quality of life and prolonging lives. We focus on therapeutic areas with a high unmet medical need, areas that require further innovation despite the progress that has been made – as for example in cancer therapy. In this context, Bayer HealthCare Pharmaceuticals focuses on its core competencies and builds on many years of research experience.

Focus on therapeutic areas with a high unmet medical need

Bayer HealthCare Pharmaceuticals concentrates the internal drug discovery of active ingredients on four core areas: Oncology, Cardiology, Gynecology, and Hematology. With new approaches in cancer therapy, cardiovascular diseases and gynecological therapies, we aim to become the innovation leader in these areas.

At a glance

Research expenses 2012	EUR 1,556 million
In percent of division sales 2012	14,5%
Employees in Research & Development	7,500 (as of Dec 31, 2012)

Information for Download

From molecules to medicine - A journey through research and development (PDF, 470 KB)

Contact Research Form

Please choose our email contact form

R&D highlights

In 2012 Bayer HealthCare invested over €1.55 billion in pharmaceutical research and development. This research effort represents about 14,5 percent of total sales in the Pharmaceuticals Division.
Worldwide, Bayer HealthCare employs 7,500 staff in pharmaceutical research and development.
More than 30 development projects in clinical trials are currently ongoing worldwide.
Bayer was awarded the Prix Galien International in 2010 and by the German President the “Deutsche Zukunftspreis” (Germany's most important innovation award) by the Federal President in 2009 for the development Rivaroxaban.
Bayer HealthCare invests continuously in expanding its innovative strength. We recently opened two new innovation centers in addition to our pharmaceutical research locations in Berlin, Wuppertal and Berkeley:
- U.S. Innovation-Center Mission Bay
- Innovation Center China (Beijing)
Bayer HealthCare collaborates with innovative partners from academia and industry in all phases of pharmaceutical research and development. We have strategic partnerships with research institutes such as the German Cancer Research Center in Heidelberg and the Tsinghua University in Beijing (China), and are actively involved in projects of the European Union's Innovative Medicines Initiative (IMI).

R & D Highlights 1

Information for Download

From molecules to medicine - A journey through research and development (PDF, 470 KB)

Contact Research Form

Please choose our email contact form

Research locations

Bayer HealthCare Pharmaceuticals is one of the leading research-based pharmaceutical companies worldwide. As a globally active company, our research and development sites are located all over the world.

In the following you will find an overview of our biggest research locations:

Berlin Germany	In Berlin, we focus our research activities in the therapeutic areas of: Oncology Gynecology Diagnostic Imaging
Wuppertal Germany	In Wuppertal our research scientists focus on the areas of: Cardiology Biologics Common Mechanism Research
Bay Area California U.S.A.	In the Bay Area, California, Bayer HealthCare runs research labs that are specialised in the areas of: Hematology Biologics Bay Area also locates our U.S. Innovation-Center,which was established in 2010 and serves as our science hub for research collaborations in the U.S.
Beijing China	Beijing locates our Innovation-Center China, which was founded in 2009; it coordinates all our research activities and collaborations in China.